{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:01:44Z","timestamp":1790755304115,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":70,"publisher":"Springer US","isbn-type":[{"value":"9781071656068","type":"print"},{"value":"9781071656075","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2027]]},"DOI":"10.1007\/978-1-0716-5607-5_9","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:46:08Z","timestamp":1790754368000},"page":"109-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunophenotyping of Acute Myeloid Leukemia"],"prefix":"10.1007","author":[{"given":"Pallavi","family":"Kanwar Galera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Braylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"7","key":"9_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O et al. (2022) The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7):1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"9_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood-2007-11-120535","volume":"2008","author":"FE Craig","year":"2008","unstructured":"Craig FE, Foon KA (2008) Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008:111. https:\/\/doi.org\/10.1182\/blood-2007-11-120535","journal-title":"Blood"},{"issue":"4","key":"9_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cll.2017.07.003","volume":"37","author":"X Chen","year":"2017","unstructured":"Chen X, Cherian S (2017) Acute myeloid leukemia immunophenotyping by flow cytometric analysis. Clin Lab Med 37(4):753\u2013769","journal-title":"Clin Lab Med"},{"issue":"1","key":"9_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cyto.b.20008","volume":"60","author":"E Van Lochem","year":"2004","unstructured":"Van Lochem E, Van der Velden V, Wind H, Te Marvelde J, Westerdaal N, Van Dongen J (2004) Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom 60(1):1\u201313","journal-title":"Cytometry B Clin Cytom"},{"key":"9_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/B978-0-12-385493-3.00010-3","volume":"103","author":"W Gorczyca","year":"2011","unstructured":"Gorczyca W, Sun Z-Y, Cronin W, Li X, Mau S, Tugulea S (2011) Immunophenotypic pattern of myeloid populations by flow cytometry analysis. Meth Cell Biol 103:221\u2013266","journal-title":"Meth Cell Biol"},{"issue":"5","key":"9_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/ajcp\/aqae187","volume":"163","author":"M Roshal","year":"2025","unstructured":"Roshal M, Gao Q (2025) Flow cytometry evaluation of acute myeloid leukemia minimal residual disease based on an understanding of the normal maturation patterns in the blast compartments. Am J Clin Pathol 163(5):775\u2013793. https:\/\/doi.org\/10.1093\/ajcp\/aqae187","journal-title":"Am J Clin Pathol"},{"key":"9_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cyto.b.20429","volume":"2009","author":"MR Loken","year":"2009","unstructured":"Loken MR, Chu SC, Fritschle W (2009) Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytometry B Clin Cytom 2009:76. https:\/\/doi.org\/10.1002\/cyto.b.20429","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"9_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.cll.2007.05.006","volume":"27","author":"BL Wood","year":"2007","unstructured":"Wood BL (2007) Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia. Clin Lab Med 27(3):551\u2013575","journal-title":"Clin Lab Med"},{"key":"9_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/cyto.b.20363","volume":"2007","author":"BL Wood","year":"2007","unstructured":"Wood BL, Arroz M, Barnett D (2007) 2006 Bethesda international consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom 2007:72. https:\/\/doi.org\/10.1002\/cyto.b.20363","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"9_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cyto.b.21239","volume":"90","author":"BL Wood","year":"2016","unstructured":"Wood BL (2016) Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom 90(1):47\u201353","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"9_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cll.2017.07.004","volume":"37","author":"J Xu","year":"2017","unstructured":"Xu J, Jorgensen JL, Wang SA (2017) How do we use multicolor flow cytometry to detect minimal residual disease in acute myeloid leukemia. Clin Lab Med 37(4):787\u2013802","journal-title":"Clin Lab Med"},{"issue":"6","key":"9_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s11899-017-0419-5","volume":"12","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Wood BL (2017) Methods of detection of measurable residual disease in AML. Curr Hematol Malign Rep 12(6):557\u2013567","journal-title":"Curr Hematol Malign Rep"},{"key":"9_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2016-08-733196","volume":"2017","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017:129. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"9_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1200\/JCO.2012.45.9628","volume":"2013","author":"M Terwijn","year":"2013","unstructured":"Terwijn M, Putten WL, Kelder A (2013) High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study. J Clin Oncol 2013:31. https:\/\/doi.org\/10.1200\/JCO.2012.45.9628","journal-title":"J Clin Oncol"},{"issue":"12","key":"9_CR15","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1182\/blood.V96.12.3948","volume":"96","author":"A Venditti","year":"2000","unstructured":"Venditti A, Buccisano F, Del Poeta G et al. (2000) Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia: Presented in part at the 41st annual meeting of the American Society of Hematology, December 3\u20137, 1999, New Orleans, LA. Blood 96(12):3948\u20133952","journal-title":"Blood"},{"issue":"20","key":"9_CR16","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","volume":"121","author":"H-H Zhu","year":"2013","unstructured":"Zhu H-H, Zhang X-H, Qin Y-Z et al. (2013) MRD-directed risk stratification treatment may improve outcomes of t (8; 21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 121(20):4056\u20134062","journal-title":"Blood"},{"key":"9_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1200\/JCO.2013.49.1753","volume":"2013","author":"SD Freeman","year":"2013","unstructured":"Freeman SD, Virgo P, Couzens S (2013) Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013:31. https:\/\/doi.org\/10.1200\/JCO.2013.49.1753","journal-title":"J Clin Oncol"},{"key":"9_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1200\/JCO.2010.31.8121","volume":"2011","author":"RB Walter","year":"2011","unstructured":"Walter RB, Gooley TA, Wood BL (2011) Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011:29. https:\/\/doi.org\/10.1200\/JCO.2010.31.8121","journal-title":"J Clin Oncol"},{"key":"9_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bbmt.2017.03.017","volume":"2017","author":"BM Getta","year":"2017","unstructured":"Getta BM, Devlin SM, Levine RL (2017) Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation. Biol Blood Marrow Transplant 2017:23. https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"9_CR20","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","volume":"26","author":"J Van Dongen","year":"2012","unstructured":"Van Dongen J, Lhermitte L, B\u00f6ttcher S et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9):1908\u20131975","journal-title":"Leukemia"},{"key":"9_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1182\/blood-2017-09-801498","volume":"2018","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S (2018) Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party. Blood 2018:131. https:\/\/doi.org\/10.1182\/blood-2017-09-801498","journal-title":"Blood"},{"key":"9_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1365-2257.1996.tb00728.x","volume":"1996","author":"JT Reilly","year":"1996","unstructured":"Reilly JT (1996) Use and evaluation of leukocyte monoclonal antibodies in the diagnostic laboratory: a review. Clin Lab Haematol 1996:18. https:\/\/doi.org\/10.1111\/j.1365-2257.1996.tb00728.x","journal-title":"Clin Lab Haematol"},{"key":"9_CR23","volume-title":"Flow cytometry: principles for clinical laboratory practice quality assurance for quantitative immunophenotyping","author":"MA Owens","year":"1995","unstructured":"Owens MA, Loken MR (1995) Quality control of flow cytometer and reagents. In: Owens MA, Loken MR (Eds.)Flow cytometry: principles for clinical laboratory practice quality assurance for quantitative immunophenotyping. Wiley"},{"key":"9_CR24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/978-1-62703-357-2_8","volume":"2013","author":"BL Wood","year":"2013","unstructured":"Wood BL (2013) Flow cytometric monitoring of residual disease in acute leukemia. Methods Mol Biol 2013:999. https:\/\/doi.org\/10.1007\/978-1-62703-357-2_8","journal-title":"Methods Mol Biol"},{"key":"9_CR25","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/978-1-4939-7142-8_4","volume":"2017","author":"W Chen","year":"2017","unstructured":"Chen W, Luu HS (2017) Immunophenotyping by multiparameter flow cytometry. Methods Mol Biol 2017:1633. https:\/\/doi.org\/10.1007\/978-1-4939-7142-8_4","journal-title":"Methods Mol Biol"},{"key":"9_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1749-6632.1993.tb38783.x","volume":"1993","author":"GT Stelzer","year":"1993","unstructured":"Stelzer GT, Shults KE, Loken MR (1993) CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci 1993:677. https:\/\/doi.org\/10.1111\/j.1749-6632.1993.tb38783.x","journal-title":"Ann N Y Acad Sci"},{"key":"9_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/ajcp\/100.5.534","volume":"1993","author":"MJ Borowitz","year":"1993","unstructured":"Borowitz MJ, Guenther KL, Shults KE (1993) Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 1993:100. https:\/\/doi.org\/10.1093\/ajcp\/100.5.534","journal-title":"Am J Clin Pathol"},{"key":"9_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1309\/AJCPN4G1IZPABRLH","volume":"2012","author":"AM Harrington","year":"2012","unstructured":"Harrington AM, Olteanu H, Kroft SH (2012) A dissection of the CD45\/side scatter \u201cblast gate\u201d. Am J Clin Pathol 2012:137. https:\/\/doi.org\/10.1309\/AJCPN4G1IZPABRLH","journal-title":"Am J Clin Pathol"},{"key":"9_CR29","first-page":"84","volume":"1999","author":"A Orfao","year":"1999","unstructured":"Orfao A, Chill\u00f3n MC, Bortoluci AM (1999) The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. Haematologica 1999:84","journal-title":"Haematologica"},{"key":"9_CR30","first-page":"127","volume":"2003","author":"SJ Kussick","year":"2003","unstructured":"Kussick SJ, Wood BL (2003) Using 4-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med 2003:127","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"9_CR31","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3324\/haematol.2009.005801","volume":"94","author":"AA van de Loosdrecht","year":"2009","unstructured":"van de Loosdrecht AA, Alhan C, Bene MC et al. (2009) Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 94(8):1124","journal-title":"Haematologica"},{"key":"9_CR32","first-page":"42","volume":"2000","author":"M Exner","year":"2000","unstructured":"Exner M, Thalhammer R, Kapiotis S (2000) The \u201ctypical\u201d immunophenotype of acute promyelocytic leukemia (APL-M3): does it prove true for the M3-variant. Cytometry 2000:42. doi:3.0.CO;2-S","journal-title":"Cytometry"},{"key":"9_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4081\/4380","volume":"2012","author":"M Takenokuchi","year":"2012","unstructured":"Takenokuchi M, Kawano S, Nakamachi Y (2012) FLT3\/ITD associated with an immature immunophenotype in PML-RAR\u03b1 leukemia. Hematol Rep 2012:4. https:\/\/doi.org\/10.4081\/4380","journal-title":"Hematol Rep"},{"key":"9_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1182\/blood-2010-04-277434","volume":"2011","author":"P Montesinos","year":"2011","unstructured":"Montesinos P, Ray\u00f3n C, Vellenga E (2011) Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 2011:117. https:\/\/doi.org\/10.1182\/blood-2010-04-277434","journal-title":"Blood"},{"key":"9_CR35","first-page":"80","volume":"1992","author":"CA Hurwitz","year":"1992","unstructured":"Hurwitz CA, Raimondi SC, Head D (1992) Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 1992:80","journal-title":"Blood"},{"key":"9_CR36","first-page":"80","volume":"1992","author":"K Kita","year":"1992","unstructured":"Kita K, Nakase K, Miwa H (1992) Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992:80","journal-title":"Blood"},{"key":"9_CR37","first-page":"90","volume":"1997","author":"MR Baer","year":"1997","unstructured":"Baer MR, Stewart CC, Lawrence D (1997) Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997:90","journal-title":"Blood"},{"key":"9_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.leukres.2013.05.002","volume":"2013","author":"N Iriyama","year":"2013","unstructured":"Iriyama N, Hatta Y, Takeuchi J (2013) CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). Leukemia Res 2013:37. https:\/\/doi.org\/10.1016\/j.leukres.2013.05.002","journal-title":"Leukemia Res"},{"key":"9_CR39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1309\/JVALJNL4ELQMD536","volume":"2007","author":"J De","year":"2007","unstructured":"De J, Zanjani R, Hibbard M (2007) Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia. Am J Clin Pathol 2007:128. https:\/\/doi.org\/10.1309\/JVALJNL4ELQMD536","journal-title":"Am J Clin Pathol"},{"key":"9_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/ajcp\/aqw038","volume":"2016","author":"J Ouyang","year":"2016","unstructured":"Ouyang J, Goswami M, Peng J (2016) Comparison of multiparameter flow cytometry immunophenotypic analysis and quantitative RT-PCR for the detection of minimal residual disease of core binding factor acute myeloid leukemia. Am J Clin Pathol 2016:145. https:\/\/doi.org\/10.1093\/ajcp\/aqw038","journal-title":"Am J Clin Pathol"},{"key":"9_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/ajcp\/107.4.430","volume":"1997","author":"R Alsabeh","year":"1997","unstructured":"Alsabeh R, Brynes RK, Slovak ML (1997) Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. Am J Clin Pathol 1997:107. https:\/\/doi.org\/10.1093\/ajcp\/107.4.430","journal-title":"Am J Clin Pathol"},{"key":"9_CR42","first-page":"20","volume":"2012","author":"YY Lai","year":"2012","unstructured":"Lai YY, Li Y, Shi Y (2012) Characteristics of 11 patients with acute myeloid leukemia accompanied with karyotype aberration t(6;9). Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012:20","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"9_CR43","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1309\/5DGB59KQA527PD47","volume":"2004","author":"MP Oyarzo","year":"2004","unstructured":"Oyarzo MP, Lin P, Glassman A (2004) Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol 2004:122. https:\/\/doi.org\/10.1309\/5DGB59KQA527PD47","journal-title":"Am J Clin Pathol"},{"key":"9_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/sj.leu.2404233","volume":"2006","author":"ML Slovak","year":"2006","unstructured":"Slovak ML, Gundacker H, Bloomfield CD (2006) A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare \u201cpoor prognosis\u201d myeloid malignancies. Leukemia 2006:20. https:\/\/doi.org\/10.1038\/sj.leu.2404233","journal-title":"Leukemia"},{"key":"9_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/sj.leu.2401639","volume":"2000","author":"J Bernstein","year":"2000","unstructured":"Bernstein J, Dastugue N, Haas OA (2000) Nineteen cases of the t(1;22)(p13;q13) acute megakaryblastic leukaemia of infants\/ children and a review of 39 cases: report from a t(1;22) study group. Leukemia 2000:14. https:\/\/doi.org\/10.1038\/sj.leu.2401639","journal-title":"Leukemia"},{"key":"9_CR46","first-page":"78","volume":"1991","author":"A Carroll","year":"1991","unstructured":"Carroll A, Civin C, Schneider N (1991) The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a pediatric oncology group study. Blood 1991:78","journal-title":"Blood"},{"key":"9_CR47","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1182\/blood-2015-02-629204","volume":"2015","author":"H Inaba","year":"2015","unstructured":"Inaba H, Zhou Y, Abla O (2015) Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. Blood 2015:126. https:\/\/doi.org\/10.1182\/blood-2015-02-629204","journal-title":"Blood"},{"issue":"5","key":"9_CR48","first-page":"423","volume":"81","author":"A Cuneo","year":"1996","unstructured":"Cuneo A, Ferrant A, Michaux JL et al. (1996) Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features. Haematologica 81(5):423\u20137","journal-title":"Haematologica"},{"issue":"12","key":"9_CR49","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/sj.leu.2401229","volume":"12","author":"E Paietta","year":"1998","unstructured":"Paietta E, Racevskis J, Bennett JM, Neuberg D, Cassileth PA, Rowe JM, Wiernik PH (1998) Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia 12(12):1881\u20135. https:\/\/doi.org\/10.1038\/sj.leu.2401229","journal-title":"Leukemia"},{"issue":"4","key":"9_CR50","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1309\/b4nver1ajj84ctuu","volume":"127","author":"CP Soupir","year":"2007","unstructured":"Soupir CP, Vergilio JA, Dal Cin P, Muzikansky A, Kantarjian H, Jones D, Hasserjian RP (2007) Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol 127(4):642\u201350. https:\/\/doi.org\/10.1309\/b4nver1ajj84ctuu","journal-title":"Am J Clin Pathol"},{"key":"9_CR51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.leu.2402708","volume":"2003","author":"L Mu\u00f1oz","year":"2003","unstructured":"Mu\u00f1oz L, Nomded\u00e9u JF, Villamor N (2003) Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia 2003:17. https:\/\/doi.org\/10.1038\/sj.leu.2402708","journal-title":"Leukemia"},{"key":"9_CR52","first-page":"86","volume":"1995","author":"U Creutzig","year":"1995","unstructured":"Creutzig U, Harbott J, Sperling C (1995) Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood 1995:86","journal-title":"Blood"},{"key":"9_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.leukres.2009.08.029","volume":"2010","author":"BC Medeiros","year":"2010","unstructured":"Medeiros BC, Kohrt HE, Arber DA (2010) Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)\/t(3;3)(q21;q26.2). Leukemia Res 2010:34. https:\/\/doi.org\/10.1016\/j.leukres.2009.08.029","journal-title":"Leukemia Res"},{"key":"9_CR54","first-page":"13","volume":"2015","author":"JM Raya","year":"2015","unstructured":"Raya JM, Mart\u00edn-Santos T, Lu\u00f1o E (2015) Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): clinical and biological features and comparison with other acute myeloid leukemias with cytogenetic aberrations involving long arm of chromosome 3. Hematology 2015:13","journal-title":"Hematology"},{"issue":"4","key":"9_CR55","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/bjh.16203","volume":"188","author":"Y Hara","year":"2020","unstructured":"Hara Y, Shiba N, Yamato G et al. (2020) Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup. Brit J Haematol 188(4):528\u2013539. https:\/\/doi.org\/10.1111\/bjh.16203","journal-title":"Brit J Haematol"},{"issue":"2","key":"9_CR56","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3324\/haematol.2019.236745","volume":"106","author":"S Noort","year":"2021","unstructured":"Noort S, Wander P, Alonzo TA et al. (2021) The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. Haematologica 106(2):630\u2013634. https:\/\/doi.org\/10.3324\/haematol.2019.236745","journal-title":"Haematologica"},{"issue":"23","key":"9_CR57","doi-asserted-by":"publisher","first-page":"6000","DOI":"10.1182\/bloodadvances.2020002712","volume":"4","author":"KM Chisholm","year":"2020","unstructured":"Chisholm KM, Heerema-McKenney AE, Choi JK et al. (2020) Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children\u2019s Oncology Group. Blood Adv 4(23):6000\u20136008. https:\/\/doi.org\/10.1182\/bloodadvances.2020002712","journal-title":"Blood Adv"},{"key":"9_CR58","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.leukres.2010.05.015","volume":"2011","author":"J Nomded\u00e9u","year":"2011","unstructured":"Nomded\u00e9u J, Bussaglia E, Villamor N (2011) Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size. Leukemia Res 2011:35. https:\/\/doi.org\/10.1016\/j.leukres.2010.05.015","journal-title":"Leukemia Res"},{"key":"9_CR59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.leukres.2013.03.009","volume":"2013","author":"YR Liu","year":"2013","unstructured":"Liu YR, Zhu HH, Ruan GR (2013) NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes. Leukemia Res 2013:37. https:\/\/doi.org\/10.1016\/j.leukres.2013.03.009","journal-title":"Leukemia Res"},{"key":"9_CR60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1078-0432.CCR-14-3186","volume":"2015","author":"DF Angelini","year":"2015","unstructured":"Angelini DF, Ottone T, Guerrera G (2015) A leukemia-associated CD34\/CD123\/CD25\/CD99+ immunophenotype identifies FLT3-mutated clones in acute myeloid leukemia. Clin Cancer Res 2015:21. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3186","journal-title":"Clin Cancer Res"},{"key":"9_CR61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1078-0432.CCR-04-1816","volume":"2005","author":"LI Lin","year":"2005","unstructured":"Lin LI, Chen CY, Lin DT (2005) Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005:11. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1816","journal-title":"Clin Cancer Res"},{"key":"9_CR62","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/sj.bjc.6605207","volume":"2009","author":"HA Hou","year":"2009","unstructured":"Hou HA, Lin LI, Chen CY (2009) Reply to \u201cheterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis\u201d. Brit J Cancer 2009:101. https:\/\/doi.org\/10.1038\/sj.bjc.6605207","journal-title":"Brit J Cancer"},{"issue":"8","key":"9_CR63","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/cyto.a.24339","volume":"99","author":"A Zangrando","year":"2021","unstructured":"Zangrando A, Cavagnero F, Scarparo P et al. (2021) CD56, HLA-DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3-GLIS2 fusion transcript. Cytometry A J Int Soc Analyt Cytol 99(8):844\u2013850. https:\/\/doi.org\/10.1002\/cyto.a.24339","journal-title":"Cytometry A J Int Soc Analyt Cytol"},{"issue":"10","key":"9_CR64","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1038\/leu.2016.119","volume":"30","author":"L Eidenschink Brodersen","year":"2016","unstructured":"Eidenschink Brodersen L, Alonzo TA, Menssen AJ et al. (2016) A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children\u2019s Oncology Group. Leukemia 30(10):2077\u20132080. https:\/\/doi.org\/10.1038\/leu.2016.119","journal-title":"Leukemia"},{"issue":"3","key":"9_CR65","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bjh.15725","volume":"184","author":"R Masetti","year":"2019","unstructured":"Masetti R, Bertuccio SN, Pession A, Locatelli F (2019) CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity. Brit J Haematol 184(3):337\u2013347. https:\/\/doi.org\/10.1111\/bjh.15725","journal-title":"Brit J Haematol"},{"issue":"5","key":"9_CR66","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/leu.2008.388","volume":"23","author":"T Haferlach","year":"2009","unstructured":"Haferlach T, Kohlmann A, Klein HU et al. (2009) AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia 23(5):934\u201343. https:\/\/doi.org\/10.1038\/leu.2008.388","journal-title":"Leukemia"},{"issue":"5","key":"9_CR67","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00277-019-03637-7","volume":"98","author":"W Xie","year":"2019","unstructured":"Xie W, Hu S, Xu J, Chen Z, Medeiros LJ, Tang G (2019) Acute myeloid leukemia with t(8;16)(p11.2;p13.3)\/KAT6A-CREBBP in adults. Ann Hematol 98(5):1149\u20131157. https:\/\/doi.org\/10.1007\/s00277-019-03637-7","journal-title":"Ann Hematol"},{"key":"9_CR68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/leu.2008.388","volume":"2009","author":"T Haferlach","year":"2009","unstructured":"Haferlach T, Kohlmann A, Klein HU (2009) AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia 2009:23. https:\/\/doi.org\/10.1038\/leu.2008.388","journal-title":"Leukemia"},{"key":"9_CR69","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.humpath.2013.03.007","volume":"2013","author":"H Dang","year":"2013","unstructured":"Dang H, Chen Y, Kamel-Reid S (2013) CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia. Human Pathol 2013:44. https:\/\/doi.org\/10.1016\/j.humpath.2013.03.007","journal-title":"Human Pathol"},{"key":"9_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-107","volume":"2013","author":"CY Chen","year":"2013","unstructured":"Chen CY, Chou WC, Tsay W (2013) Hierarchical cluster analysis of immunophenotyped classify AML patients with NPM1 gene mutation into two groups with distinct prognosis. BMC Cancer 2013: 13. https:\/\/doi.org\/10.1186\/1471-2407-13-107","journal-title":"BMC Cancer"}],"container-title":["Methods in Molecular Biology","Immunophenotyping"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5607-5_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:46:11Z","timestamp":1790754371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5607-5_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"ISBN":["9781071656068","9781071656075"],"references-count":70,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5607-5_9","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}